There is no evidence that DHEA  improves quality of life but there is some evidence that it is associated with and rogenic side effects .
There is uncertainty whether DHEA decreases menopausal symptoms , but DHEA may slightly improve sexual function compared with placebo
BACKGROUND During menopause a decreasing ovarian follicular response generally causes a fluctuation and eventual decrease in estrogen levels .
This can lead to the development of various perimenopausal and postmenopausal symptoms ( for example hot flushes , night sweats , vaginal dryness ) .
Dehydroepi and rosterone ( DHEA ) is one of the main precursors of and rogens , which in turn are converted to testosterone and estrogens .
It is possible that the administration of DHEA may increase estrogen and testosterone levels in peri- and postmenopausal women to alleviate their symptoms and improve general wellbeing and sexual function ( for example libido , dyspareunia , satisfaction ) .
Treatment with DHEA is controversial as there is uncertainty about its effectiveness and safety .
This review should clearly outline the evidence for DHEA in the treatment of menopausal symptoms and evaluate its effectiveness and safety by combining the results of r and omised controlled trials .
OBJECTIVES To assess the effectiveness and safety of administering DHEA to women with menopausal symptoms in the peri- or postmenopausal phase .
Oral dehydroepiandrosterone in physiologic doses modulates immune function in postmenopausal women.
OBJECTIVE This study tests the hypothesis that dehydroepi and rosterone or its metabolic products are immunomodulatory in postmenopausal women with relative adrenal and rogen deficiency . STUDY DESIGN A prospect i ve , r and omized , double-blind , crossover study of 11 subjects with 3-week treatment arms separated by a 2-week washout period was performed . Immunologic evaluation at the beginning and end of the treatment arms consisted of flow cytometry to delineate T-cell population s , in vitro T-cell mitogenic response and cytokine production , and natural killer cell cytotoxicity . Statistical analysis was based on a split-plot design with analysis of variance with repeated measures . RESULTS Dehydroepi and rosterone supplementation decreased CD4 + ( helper ) T cells and increased CD8+/CD56 + ( natural killer ) cells . Although T-cell mitogenic and interleukin-6 responses were inhibited , natural killer cell cytotoxicity increased dramatically . CONCLUSIONS These data provide the first in vivo evidence in human for an immunomodulatory effect of dehydroepi and rosterone . The salutary immune changes could account for clinical and experimental evidence of antioncogenic effects of this steroid . This study provides a strong rationale for further clinical studies on dehydroepi and rosterone supplementation in adrenal and rogen-deficient states
There is no evidence that DHEA  improves quality of life but there is some evidence that it is associated with and rogenic side effects .
There is uncertainty whether DHEA decreases menopausal symptoms , but DHEA may slightly improve sexual function compared with placebo
BACKGROUND During menopause a decreasing ovarian follicular response generally causes a fluctuation and eventual decrease in estrogen levels .
This can lead to the development of various perimenopausal and postmenopausal symptoms ( for example hot flushes , night sweats , vaginal dryness ) .
Dehydroepi and rosterone ( DHEA ) is one of the main precursors of and rogens , which in turn are converted to testosterone and estrogens .
It is possible that the administration of DHEA may increase estrogen and testosterone levels in peri- and postmenopausal women to alleviate their symptoms and improve general wellbeing and sexual function ( for example libido , dyspareunia , satisfaction ) .
Treatment with DHEA is controversial as there is uncertainty about its effectiveness and safety .
This review should clearly outline the evidence for DHEA in the treatment of menopausal symptoms and evaluate its effectiveness and safety by combining the results of r and omised controlled trials .
OBJECTIVES To assess the effectiveness and safety of administering DHEA to women with menopausal symptoms in the peri- or postmenopausal phase .